Global Continuous Renal Replacement Therapy (CRRT) Market is set to witness a CAGR of 7% to 9% by 2027 - Key Market Players are Baxter, B. Braun, Fresenius Medical Care, Medtronic, Nipro

Continuous Renal Replacement Therapy (CRRT) is a slow form of dialysis which removes additional fluids and waste products from the blood in a continuous manner, similar to the way the kidneys function in healthy people.

Adoption of Continuous Renal Replacement Therapy for the Treatment of Sick Patients with Acute Kidney Injury (AKI) Diseases

AKI is a global problem and is most common among severely sick patients. It is projected that approximately 13.3 million patients globally are affected by AKI per year, ~85% of whom live in the developing countries. The major aim of Continuous Renal Replacement Therapy for severely sick patients with AKI diseases are maintaining fluid, electrolyte, acid-base, and solute balance, supporting renal recovery, and allowing other supportive interventions to further proceed without any new complication or disadvantage.

Several Benefits Associated with Continuous Renal Replacement Therapy Drives the Growth of the CRRT Market

Hemodynamic instability is most common among severally sick patients with AKI receiving RRT. Continuous Renal Replacement Therapy may have a good hemodynamic profile compared with other intermittent therapies, including intermittent hemodialysis and sustained low-efficiency dialysis. Among the CRRT's benefits, the key benefit is the prevention of changes in intracerebral water. CRRT is also considered much safer than IHD in patients at risk of cerebral edema.

An Increasing Awareness on Kidney Health and Prevention Program Triggers the Growth of the Continuous Renal Replacement Therapy Market

Presently, a higher number of kidney health & prevention programs are being run by leading organizations such as National Kidney Foundation (NKF), The National Kidney Disease Education Program (NKDEP), and local governments all across the world to improve awareness on evidence-based interventions to enhance the understanding, detection and management of various kidney diseases.

Covid-19 Impact on the Global CRRT Market

Globally, healthcare systems had been affected by the COVID-19 pandemic. During the covid-19 pandemic, approximately 15%-30% of patients with COVID-19 admitted to the ICU were showing symptoms of kidney failure and they needed CRRT. In such scenarios, continuous renal replacement therapy acted as a life-saving therapy.

Key Market Challenges : Continuous Renal Replacement Therapy Market

The higher costs of the CRRT procedures and the risks & complications associated with continuous renal replacement therapies such as catheter-related complications, blood loss, infection or access failure, fluctuations in salt balance, hemodialysis-related complications, coagulopathy, and venous thrombosis are likely to impact the growth of the global continuous renal replacement therapy market.

North America is Set to Hold a Higher Market Share in the CRRT Market

From a geographical overview, North America is projected to hold a higher market share in the global continuous renal replacement therapy market. This can be mainly attributed to the growing cases of AKI, technological innovations in CRRT products, and a significant rise in the number of diabetic patients in this region.

Competitive Landscape Analysis: Continuous Renal Replacement Therapy Market

Some of the leading and emerging players operating in the global continuous renal replacement therapy market are Baxter, B. Braun, Fresenius Medical Care AG, Medtronic, and Nipro Corporation, etc.

Get Detailed Insights on Continuous Renal Replacement Therapy (CRRT) Market @ https://meditechinsights.com/continuous-renal-replacement-therapy-market/

Ruta Halde
Associate, Medi-Tech Insights
121/7E Avenue Franklin Roosevelt,
1050 Brussels, Belgium
+32 498 86 80 79
info@meditechinsights.com
https://meditechinsights.com/

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

This release was published on openPR.